These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 27251502)

  • 1. Effect of a Ferric Citrate Formulation, a Phosphate Binder, on Oxidative Stress in Chronic Kidney Diseases-Mineral and Bone Disorder Patients Receiving Hemodialysis: A Pilot Study.
    Tanaka M; Miyamura S; Imafuku T; Tominaga Y; Maeda H; Anraku M; Yamasaki K; Kadowaki D; Ishima Y; Watanabe H; Okuda T; Itoh K; Matsushita K; Fukagawa M; Otagiri M; Maruyama T
    Biol Pharm Bull; 2016; 39(6):1000-6. PubMed ID: 27251502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ferric citrate controls serum phosphorus in dialysis patients: retrospective data
.
    Hain DJ; Marinaro M; Koeper DW; Rosenthal MA; Chillemi S; Huffman JM; Gerbeling T; Pritsiolas JM; Loram LC; Pergola PE
    Clin Nephrol; 2017 Jul; 88(1):12-18. PubMed ID: 28561732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5.
    Block GA; Fishbane S; Rodriguez M; Smits G; Shemesh S; Pergola PE; Wolf M; Chertow GM
    Am J Kidney Dis; 2015 May; 65(5):728-36. PubMed ID: 25468387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety and tolerability of ferric citrate as a phosphate binder in dialysis patients.
    Sinsakul M; Sika M; Koury M; Shapiro W; Greene T; Dwyer J; Smith M; Korbet S; Lewis J;
    Nephron Clin Pract; 2012; 121(1-2):c25-9. PubMed ID: 23075669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety and efficacy of a novel iron-containing phosphate binder, JTT-751, in patients receiving hemodialysis.
    Yokoyama K; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Chertow GM; Hirakata H
    J Ren Nutr; 2014 Jul; 24(4):261-7. PubMed ID: 24836401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of ferric citrate and intravenous iron sucrose on markers of mineral, bone, and iron homeostasis in a rat model of CKD-MBD.
    Biruete A; Metzger CE; Chen NX; Swallow EA; Vrabec C; Clinkenbeard EL; Stacy AJ; Srinivasan S; O'Neill K; Avin KG; Allen MR; Moe SM
    Nephrol Dial Transplant; 2022 Sep; 37(10):1857-1867. PubMed ID: 35482713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Ferric Citrate in Hyperphosphatemia and Iron Deficiency Anemia in Non Dialysis CKD Patients.
    Nand N; Giri K; Jain D
    J Assoc Physicians India; 2019 Apr; 67(4):53-56. PubMed ID: 31311220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regional prescription surveillance of phosphate binders in the western Saitama area: the substantial role of ferric citrate hydrate in improving serum phosphorus levels and erythropoiesis.
    Amano H; Ohno Y; Inoue T; Tomori K; Ohama K; Okada H
    Clin Exp Nephrol; 2019 Jun; 23(6):841-851. PubMed ID: 30783915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sucroferric oxyhydroxide decreases serum phosphorus level and fibroblast growth factor 23 and improves renal anemia in hemodialysis patients.
    Shima H; Miya K; Okada K; Minakuchi J; Kawashima S
    BMC Res Notes; 2018 Jun; 11(1):363. PubMed ID: 29884226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Pilot Randomized Trial of Ferric Citrate Coordination Complex for the Treatment of Advanced CKD.
    Block GA; Block MS; Smits G; Mehta R; Isakova T; Wolf M; Chertow GM
    J Am Soc Nephrol; 2019 Aug; 30(8):1495-1504. PubMed ID: 31278194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphate Binder, Ferric Citrate, Attenuates Anemia, Renal Dysfunction, Oxidative Stress, Inflammation, and Fibrosis in 5/6 Nephrectomized CKD Rats.
    Jing W; Nunes ACF; Farzaneh T; Khazaeli M; Lau WL; Vaziri ND
    J Pharmacol Exp Ther; 2018 Oct; 367(1):129-137. PubMed ID: 30093458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ferric citrate spans mineral metabolism and anemia domains in ESRD: a review of efficacy and safety data.
    Sinsakul M; Rodby R; Umanath K; Niecestro R; Dwyer JP
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):705-10. PubMed ID: 25242077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical experience with the use of ferric citrate as a phosphate binder in pediatric dialysis patients.
    Hanudel MR; Laster M; Ramos G; Gales B; Salusky IB
    Pediatr Nephrol; 2018 Nov; 33(11):2137-2142. PubMed ID: 29956006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial.
    Dwyer JP; Sika M; Schulman G; Chang IJ; Anger M; Smith M; Kaplan M; Zeig S; Koury MJ; Blumenthal SS; Lewis JB;
    Am J Kidney Dis; 2013 May; 61(5):759-66. PubMed ID: 23369827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ferric citrate controls phosphorus and delivers iron in patients on dialysis.
    Lewis JB; Sika M; Koury MJ; Chuang P; Schulman G; Smith MT; Whittier FC; Linfert DR; Galphin CM; Athreya BP; Nossuli AK; Chang IJ; Blumenthal SS; Manley J; Zeig S; Kant KS; Olivero JJ; Greene T; Dwyer JP;
    J Am Soc Nephrol; 2015 Feb; 26(2):493-503. PubMed ID: 25060056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD.
    Yokoyama K; Hirakata H; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Block GA
    Clin J Am Soc Nephrol; 2014 Mar; 9(3):543-52. PubMed ID: 24408120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis.
    Umanath K; Sika M; Niecestro R; Connelly C; Schulman G; Koury MJ; Lewis JB; Dwyer JP;
    Hemodial Int; 2013 Jan; 17(1):67-74. PubMed ID: 22702490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function in a mouse model of chronic kidney disease.
    Francis C; Courbon G; Gerber C; Neuburg S; Wang X; Dussold C; Capella M; Qi L; Isakova T; Mehta R; Martin A; Wolf M; David V
    Kidney Int; 2019 Dec; 96(6):1346-1358. PubMed ID: 31668632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term safety and efficacy of ferric citrate in phosphate-lowering and iron-repletion effects among patients with on hemodialysis: A multicenter, open-label, Phase IV trial.
    Lee CT; Lee CC; Wu MJ; Chiu YW; Leu JG; Wu MS; Peng YS; Wu MS; Tarng DC
    PLoS One; 2022; 17(3):e0264727. PubMed ID: 35239732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conventional and novel impacts of ferric citrate on iron deficiency anemia and phosphorus metabolism in rats.
    Iida A; Matsushita M; Ohta T; Yamada T
    J Vet Med Sci; 2020 Mar; 82(3):379-386. PubMed ID: 31996496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.